acetylcysteine has been researched along with fluticasone in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
de Backer, WA; Demkow, U; Górecka, D; van Overveld, FJ; Zielinski, J | 1 |
Akkermans, R; Chavannes, N; Dekhuijzen, R; Muris, J; Schermer, T; van Schayck, O; van Weel, C; Wouters, E | 1 |
2 trial(s) available for acetylcysteine and fluticasone
Article | Year |
---|---|
New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine.
Topics: Acetylcysteine; Administration, Inhalation; Adrenal Cortex Hormones; Adult; Androstadienes; Anti-Inflammatory Agents; Antioxidants; Double-Blind Method; Eosinophil Cationic Protein; Expectorants; Female; Fluticasone; Forced Expiratory Volume; Glutathione Peroxidase; Humans; Intercellular Adhesion Molecule-1; Interleukin-8; Male; Oxidative Stress; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Sputum; Treatment Outcome | 2005 |
Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis.
Topics: Acetylcysteine; Adult; Aged; Androstadienes; Bronchitis, Chronic; Bronchodilator Agents; Expectorants; Female; Fluticasone; Forced Expiratory Volume; Humans; Male; Middle Aged; Netherlands; Primary Health Care; Pulmonary Disease, Chronic Obstructive; Quality of Life; Smoking; Treatment Outcome | 2009 |
1 other study(ies) available for acetylcysteine and fluticasone
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |